Ehlers-Danlos Syndrome: Hypermobility Type

Condition: Ehlers-Danlos Syndrome: Hypermobility Type  |  Category: Neurological and Connective Tissue Health  |  Reviewed by: Brian Lamkin, DO

What Is Hypermobile Ehlers-Danlos Syndrome?

Hypermobile Ehlers-Danlos syndrome (hEDS) is a heritable connective tissue disorder in which defects in collagen or extracellular matrix proteins produce generalized joint hypermobility, chronic musculoskeletal pain, tissue fragility, and a constellation of systemic manifestations spanning the cardiovascular, gastrointestinal, neurological, and immune systems. It is the most common subtype of Ehlers-Danlos syndrome and the only subtype without a confirmed genetic marker, making diagnosis clinical rather than genetic.

hEDS is not simply "being double-jointed." The connective tissue laxity is systemic, affecting not only joints but blood vessel walls (contributing to orthostatic intolerance and POTS), the gastrointestinal tract (producing motility dysfunction), and the extracellular environment in which mast cells reside (potentially contributing to mast cell activation syndrome). This multisystem involvement explains why hEDS patients are seen by rheumatology, cardiology, gastroenterology, allergy, and pain management in isolated specialty encounters that rarely connect the systemic pattern.

Why It Matters

Common Symptoms

Root Causes: A Functional Medicine Perspective

The connective tissue defect in hEDS is genetic and cannot be corrected. However, the downstream consequences that produce the majority of the symptom burden are modifiable and treatable. Functional medicine identifies and addresses these downstream systems.

Joint Instability and Central Sensitization

Ligamentous laxity produces chronic joint instability, recurrent subluxation, and microtrauma. Muscles compensate by maintaining continuous tension to stabilize joints, producing the muscular pain and fatigue that hEDS patients experience daily. Over time, chronic nociceptive input from unstable joints drives central sensitization, the same pain amplification mechanism seen in fibromyalgia. Targeted physical therapy focused on joint stabilization and proprioceptive training is the foundation of pain management.

Autonomic Dysfunction

Vascular connective tissue laxity produces excessive venous pooling in the lower extremities and abdomen upon standing, reducing venous return and triggering the compensatory tachycardia that defines POTS. This is not a cardiac problem; it is a connective tissue problem with cardiovascular consequences. Fatigue and brain fog in hEDS patients are frequently driven by cerebral hypoperfusion from this autonomic mechanism rather than by depression or deconditioning.

Mast Cell Instability

The extracellular matrix environment in which mast cells reside is altered in connective tissue disorders, potentially lowering the threshold for mast cell degranulation. Mast cell activation in hEDS patients produces flushing, GI reactivity, urticaria, and medication sensitivity that compound the already complex symptom picture. Mast cell evaluation is a required component of comprehensive hEDS assessment.

Inflammatory and Nutritional Burden

Chronic pain and autonomic dysfunction produce elevated cortisol and HPA axis dysregulation. Nutritional deficiency from GI dysmotility and malabsorption is common. Vitamin D deficiency, magnesium depletion, and B vitamin insufficiency compound the pain, fatigue, and autonomic dysfunction. Inflammatory markers including hs-CRP are frequently elevated from the chronic pain and immune activation burden.

Conventional vs Functional Medicine Approach

Key Labs to Evaluate

While hEDS is a clinical diagnosis, laboratory evaluation identifies the inflammatory, nutritional, and hormonal contributors to the downstream symptom burden.

How to Interpret These Labs Together

Common Patterns Seen in Patients

• The lifelong "clumsy" patient diagnosed with fibromyalgia: Chronic widespread pain since adolescence. Diagnosed with fibromyalgia at 30. Beighton score 7/9. Recurrent ankle sprains, TMJ dysfunction, and easy bruising throughout her life. The fibromyalgia label was correct (she had central sensitization) but the underlying connective tissue disorder driving the nociceptive input was never identified.
• The POTS patient with recurrent joint injuries: Diagnosed with POTS at 24. Active standing test confirmed. History of bilateral patellar subluxation, shoulder dislocation during sleep, and chronic neck pain. Beighton score 6/9. The POTS was driven by vascular laxity from the same connective tissue disorder producing the joint instability. Both conditions were expressions of one systemic process.
• The full triad patient seen by seven specialists: Rheumatology for joint pain, cardiology for tachycardia, gastroenterology for bloating and nausea, allergy for urticaria and flushing, pain management for chronic pain, psychiatry for anxiety, and primary care coordinating referrals. Seven specialists, seven isolated treatment plans, zero recognition that hEDS was the connecting tissue disorder producing POTS and MCAS as downstream consequences.
• The teenager dismissed as having growing pains: Joint pain, fatigue, and dizziness interfering with school. Attributed to growing pains and school avoidance. Beighton score 8/9, active standing test positive for POTS, vitamin D 16 ng/mL, ferritin 9. Three treatable findings (POTS, vitamin D deficiency, iron deficiency) on a connective tissue foundation that was never assessed.

Treatment and Optimization Strategy

Integrated Multisystem Management

hEDS treatment requires addressing the downstream consequences of the connective tissue disorder across all affected systems simultaneously. Isolated treatment of pain, autonomic dysfunction, or GI symptoms without recognizing their shared connective tissue origin produces incomplete and fragmented results.

What Most Doctors Miss

• Joint hypermobility is not screened for as a systemic condition: the Beighton score takes 2 minutes to perform and identifies the connective tissue substrate underlying chronic pain, autonomic dysfunction, and GI symptoms in a significant number of complex patients
• The MCAS-POTS-EDS triad is not evaluated as a pattern: each component is seen by a different specialist, and the connecting diagnosis is never made. When a patient has unexplained tachycardia, chronic pain, and episodic flushing, the Beighton score should be the first assessment performed.
• Fibromyalgia in a hypermobile patient has a connective tissue cause: the central sensitization is driven by chronic nociceptive input from unstable joints. Treating fibromyalgia without addressing joint instability treats the consequence without addressing the cause.
• Nutritional deficiency from GI dysmotility is not identified: vitamin D, iron, magnesium, and B vitamin deficiency from malabsorption compound every system affected by the connective tissue disorder and are directly treatable.

When to Seek Medical Care

If you have chronic joint pain with a history of joint hypermobility, recurrent subluxation or dislocation, easy bruising, orthostatic intolerance, GI dysmotility, or if you have been diagnosed with fibromyalgia or POTS without evaluation for an underlying connective tissue disorder, comprehensive assessment is warranted. This is especially important if you have family members with similar symptoms or diagnoses.

At The Lamkin Clinic, hEDS evaluation includes Beighton scoring, autonomic testing, inflammatory and nutritional markers, and screening for concurrent MCAS and POTS, reviewed as an integrated connective tissue and multisystem profile.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches Hypermobile EDS

At The Lamkin Clinic, hEDS evaluation includes Beighton scoring and the 2017 diagnostic criteria, autonomic testing for POTS, mast cell mediator screening when indicated, comprehensive inflammatory and nutritional markers, and GI assessment. Treatment is built as an integrated multisystem protocol: joint stabilization, autonomic management, mast cell treatment when present, nutritional repletion, and anti-inflammatory support, all coordinated under a single connective tissue framework.

Related Conditions

Related Symptoms